Vifor Pharma AG

Vifor Pharma AG

Vifor Pharma AG

Date Founded



Rechenstrasse 37,St. Gallen, Sankt Gallen (St Gall) 9014

Type of Company


Employees (Worldwide)



Wholesale: Consumer Non-Durables/Sundries
Retail: Drug Stores

Company Description

Vifor Pharma AG is a pharmaceutical company, which engages in the research, development, production, and marketing of therapeutic products. It offers products for iron deficiency, nephrology, and cardio-renal therapies. It operates through the following geographical segments: Switzerland, Europe, USA, Rest of World, and Group. The company was founded in 1927 and is headquartered in St. Gallen, Switzerland.

Contact Data
Trying to get in touch with decision makers at Vifor Pharma AG? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Business Officer

Chief Medical Officer

Chief Executive Officer, Galenica Santé

Chief Executive Officer, Vifor Pharma

Head of Legal

General Secretary

Executive Chairman

President & Chief Operating Officer

Chief Financial Officer

Chief Human Resources Officer & Senior Vice President

Board of Directors

Executive Chairman at Vifor Pharma AG

Former General Counsel & Member of the Executive Board at Credit Suisse Group AG

Chief Executive Officer, Vifor Pharma at Vifor Pharma AG

Deputy Chairman-Executive Board at Speedel Pharma AG

Co-Founder at EOS SpA

Head of International Commercial at Shire Plc

Paths to Vifor Pharma AG
Potential Connections via
Relationship Science
Vifor Pharma AG
Owners & Shareholders
Details Hidden

Alecta is a risk-averse manager which aims to meet the requirements of long-term pension fund management, in terms of delivering a competitive return with prudent risk management. The firm's portfolio holdings consist of approximately 50 percent fixed income, 41 percent equities, and 9 percent real estate. The core of Alecta's philosophy is a competent independent in-house analysis, focusing on the absolute return and risks of their investments. They direct their investment activities mainly to areas where the firm have such in-house capability and expertise. By limiting the number of holdings, they facilitate an even deeper analysis whereby each specific analysis can have a significant impact on the firm's performance.

Details Hidden

Oddo BHF AM is an active, long-term manager that offers a unique range of effective investment solutions on all main asset classes: European equities, corporate bonds (investment grade and high yield), convertible bonds and asset allocation solutions. The firm invests globally in a variety of asset classes including equity, fixed-income, convertible bonds, money market instruments, alternative assets and private equity. They have special expertise in mid-caps, theme investing, and quantitative equity management and manage a range of strategies including money market, hedge, balanced, active asset allocation, structured products and multimanager. Oddo BHF AM follows a bottom-up approach based on in-house fundamental research to select stocks and exploit market inefficiencies. The investment process differs for each asset class, within a strategic asset allocation framework. Oddo BHF AM's investment philosophy emphasizes teamwork with autonomy for each team. Their equity and fixed-income teams operate in close relationship, using a combination of quantitative and fundamental analysis.

Details Hidden

Mirabeaud Suisse is an active, convictions-based, benchmark-aware manager which helps portfolio managers to make informed decisions and generate performance while protecting investors on the downside. They are an asset allocation and multi-asset portfolio management specialist which bases their investment process on qualitative, quantitative and technical inputs with different risk-return profiles and levels of reactivity in order to match investor needs.For equities, the firm selects stocks based on conviction, flexibility and integrated risk management. They focus on specific segments of the fixed-income universe, offering investors innovative investment solutions using credit, duration and convexity as sources of performance. They are geared towards asymmetry and offset their equity upside participation with a bond floor for downside protection.Mirabaud Suisse combines investment grade, high yield and government bonds in dynamic ways to generate positive total returns, including during interest normalization phases. Their dynamic approach for multi asset portfolios allows them to capture smaller trends and deliver performance while protecting the downside.

Recent Transactions
Details Hidden

Vifor Pharma AG, Vifor (International) AG purchase ChemoCentryx, Inc. from GlaxoSmithKline Plc

Details Hidden

Galenica AG purchases Bahnhof Apotheke im Hauptbahnhof Zürich from Vifor Pharma AG

Details Hidden

purchases Galenica AG /Galenica Sante Division from Vifor Pharma AG

Transaction Advisors
Legal Advisor

Advised onVifor Pharma AG purchases Relypsa, Inc.


Advised onVifor Pharma AG purchases Pharma-Singer AG

Investment Advisor

Advised onVifor Pharma AG purchases MediService AG

Legal Advisor

Advised onVifor Pharma AG purchases Relypsa, Inc.

Legal Advisor

Advised onVifor Pharma AG purchases Relypsa, Inc.


China Medical System Holdings Limited (“CMS”, together with its subsidiaries, the "Group") is a pharmaceutical services provider based in China, focusing on marketing promotion and sales of prescription drugs to all therapeutic departments in hospitals. The Group was established in 1995, and was listed on AIM in London (ticker: CMSH) in June 2007, the Group was listed on Main Board Market in Hong Kong on 28 September 2010 while it was delisted on AIM at the same time. The Group follows two business models which can be commonly found in the pharmaceutical industry in China, the Direct Academic Orientated Promotion Model and Agency Promotion Model, and with two distinct third party promotion networks, the Direct Academic Orientated Promotion Network (the “Direct Network”) and the Agency Promotion Network (the “Agency Network”), both of which hold leading positions in the Chinese market. On the 3 April 2011, the Group successfully acquired Great Move Enterprise Limited (“Great Move”) and its subsidiaries, the main wholly subsidiary of Great Move is Tianjin Precede Medical Trade Development Co., Ltd.(which has been officially renamed Tianjin Kangzhe Pharmaceutical Technology Development Co., Ltd.on 24 October 2011), which mainly engages in the marketing, promotion and sales of prescription pharmaceutical products manufactured by domestic pharmaceutical companies via Agency Network in China. After the acquisition, the Group` business model evolved from simply depending on internal marketing and promotion team to promote and sell products directly to physicians (Direct Academic Orientated Promotion Model) to a new integrated development model that incorporates the independent third party sales representatives and distributors to sale and promote products (Agency Promotion Model) in China. On the 31 May 2011, the Group successfully acquired 51% equity interests of Guangming Pharmaceutical Co., Ltd. (which has been officially renamed Guangxi Kangzhe Guangming Pharmaceutical Co., Ltd. on 10 October 2011) via cash investment for capital and stock increase to gain the permanent China market rights of a type of enteral nutrition drug-“Protein Hydrolysate”. The speedy introduction of this product is the result of the combination of the professional academic ability from our Direct Network and the rapid market coverage ability of our Agency Network. We introduce drugs that prove to be competitive and focus on providing marketing, promotion and sales services to specialty pharmaceutical companies by leveraging our successful product selection system and the insights in Chinese pharmaceutical market. As at 31 December 2011, the Direct Network of the Group had close to 1,200 sales, marketing and promotion professionals; the Agency Network had close to 1,000 independent third party sales representatives or distributors and around a hundred of senior regional and marketing managers. The Group`s sales coverage spanned over 14,600 hospitals throughout China, of which almost 8,600 hospitals were covered by the Direct Network and over 7,800 hospitals were covered by the Agency Network. The Group follows a market-oriented product selection strategy and introduces prescription drugs with high growth potential under its Direct Academic Orientated Promotion Model. We formulate appropriate marketing strategies for each drug, leveraging the insights in the Chinese pharmaceutical market, prevailing treatment protocols of physicians, demographic profile of the relevant patient pool in China and potential competitive advantages of drugs. Meanwhile, in order to help drive demand for pharmaceutical products, our professional, stable and experienced marketing, promotion and sales team conducts various physician-oriented academic promotion activities such as one-on-one physician visits, medical symposia and industry conferences, and via our proprietary information management system to keep track of these activities and review operations in a timely manner, enabling us to manage our overall business effectively and efficiently. In addition, the Group also provides other ancillary services needed by pharmaceutical companies to introduce their products to China, including handling product registration, clinical trials, and bidding in collective tender processes. With appropriate product positioning, strategic planning and execution, the Group gained remarkable performance. From 2007 to 2011, the compound annual growth rate (CAGR) of revenue was 42.0%, and the CAGR of net profit achieved 63.7%. We also received a number of recognitions, including the Group was ranked in the list of Forbes “Asia’s Best 200 Enterprises Under a Billion” in 2008 and “Top 100 Enterprises in Shenzhen” in 2009, 2010 and 2011, and we also gained Forbes “China’s Best Up-and-Coming Business” three times in 2010, 2011 and 2012. As a leading China-based pharmaceutical services company, the Group established long-term business partnership with specialty pharmaceutical companies from Germany, Denmark, Ireland, France, Ukraine, Japan and China. We will continuously introduce new products and extend marketing, promotion and sales network to strengthen our leading position in Chinese pharmaceutical service market, and through the professional and quality service to catch opportunities from the enormous growth of Chinese pharmaceutical market and strives to become the preferred partner for overseas and domestic pharmaceutical companies who target at Chinese market.

Fresenius Medical Care AG & Co. KGaA engages in the provision of products and services for patients with chronic kidney failure. It also develop and manufacture a variety of health care products, which includes dialysis and non-dialysis products. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

Merck KGaA is a science and technology company, which engages in the manufacture of pharmaceutical and chemical products. It operates through the following sectors: Healthcare, Life Science, and Performance Materials. The Healthcare sector discovers, develops, and produces prescription medicines used to treat cancer, multiple sclerosis, and infertility. The Life Science sector provides scientists with laboratory materials, technologies, and services. The Performance Materials sector offers specialty chemicals and materials for demanding applications. The firm offers pharma and biopharma manufacturing, pharmaceutical research, pharma quality control, and government and academic research services. The company was founded by Friedrich Jacob Merck in 1668 and is headquartered in Darmstadt, Germany.

Key Stats and Financials As of 2018
Market Capitalization
Total Enterprise Value
Earnings Per Share
Net Profit
Total Debt
Total Equity
Enterprise Value Sales
Enterprise Value EBITDAOperating
TEVNet Income
Debt TEV
Three Year Compounded Annual Growth Rate Of Revenue
Five Year Compounded Annual Growth Rate Of Revenue
Details Hidden

Genedata AG transforms data into intelligence with a portfolio of advanced software solutions. Its products include biologics, screener, expressionist, profiler, analyst, phylosospher, selector, imagence and bioprocess. The firm offers data analysis, information technology, training, software, development and hosting services to pharmaceutical, agrochemical, Industrial biotechnology companies and non-profit research organizations. The company was founded by Othmar Pfannes in 1997 and is headquartered in Basel, Switzerland.

Roche Holding AG Medical Support Services | Basel, BS

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Relypsa, Inc. Pharmaceuticals | REDWOOD CITY, CA

Relypsa, Inc. operates as a bio-pharmaceutical company, which is focused on the development and commercialization of polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. The company was founded by Jerry M. Buysse, Gerrit Klaerner, Michael Burdick, Jay P. Shepard, Detlef F. Albrecht, George Tyson, Sandra I. Coufal and Vic Ciaravino on October 29, 2007 and is headquartered in Redwood City, CA.

Pfizer, Inc. Medical Support Services | New York, NY

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Vifor Pharma AG. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Vifor Pharma AG's profile does not indicate a business or promotional relationship of any kind between RelSci and Vifor Pharma AG.